Fundz

Empyrean Neuroscience Launches With $22M Series A And Genetic Engineering Platform To Advance Pipeline Of Neuroactive Compounds Targeting Cns Disorders

PRIVATEOct 18, 2022

Amount Raised

$22 Million

Round Type

Series A

New YorkBiotechnologyTherapeutics

Description

Empyrean Neuroscience, Inc., a leading genetic engineering company dedicated to developing neuroactive compounds to treat neuropsychiatric and neurologic disorders, today announced that it has launched with a $22 million Series A financing and a genetic engineering platform to advance a pipeline of neuroactive compounds targeting disorders of the central nervous system (CNS). The company is founded on a proprietary platform designed to genetically engineer small molecule therapeutics from fungi and plants. Veteran biotech executives Usman “Oz” Azam, M.D., Chief Executive Officer, and Fred Grossman, D.O., FAPA, Chief Medical Officer, lead the company.

Quick answer

Empyrean Neuroscience raised $22 Million in a Series A round, dated October 18, 2022. Empyrean Neuroscience is based in New York, United States.

How much did Empyrean Neuroscience raise?
Empyrean Neuroscience raised $22 Million in a Series A round on October 18, 2022.
What does Empyrean Neuroscience do?
Empyrean Neuroscience is a genetic engineering company developing a pipeline of neuroactive therapeutics to treat a range of neuropsychiatric and neurologic disorders.
Where is Empyrean Neuroscience based and how big is it?
Empyrean Neuroscience is based in New York, United States.

Source: Fundz verified event record.

Who to call at Empyrean Neuroscience, and when

A new round usually means Empyrean Neuroscience is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Empyrean Neuroscience raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Empyrean Neuroscience, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Empyrean Neuroscience. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Empyrean Neuroscience

Location

New York, United States

About

Empyrean Neuroscience is a genetic engineering company developing a pipeline of neuroactive therapeutics to treat a range of neuropsychiatric and neurologic disorders. Through precision genetic modification, transformation, and regeneration of fungi and plants, the platform allows for the creation of small molecule therapeutics. In addition, the platform enables the discovery of novel small molecules that may exhibit therapeutic properties. The company is based in New York City and Cambridge, UK.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Empyrean Neuroscience raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Empyrean Neuroscience's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

Empyrean Neuroscience raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.